Predicting therapy response by analysis of metastasis founder cells: emerging perspectives for personalized tumor therapy

References

• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30;364(26):2507–2516.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358–365.
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380–2388.
   PubMed Web of Science ®Google Scholar
• Klein CA. Selection and adaptation during metastatic cancer progression. Nature. 2013 Sep 19;501(7467):365–372.
   PubMed Web of Science ®Google Scholar
• Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011 Oct 14;147(2):275–292.
   PubMed Web of Science ®Google Scholar
• Riethdorf S, Wikman H, Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer. 2008 Nov 1;123(9):1991–2006.
   PubMed Web of Science ®Google Scholar
• Toss A, Mu Z, Fernandez S, et al. CTC enumeration and characterization: moving toward personalized medicine. Ann Translat Med. 2014 Nov;2(11):108.
   PubMedGoogle Scholar
• Dillekas H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 2019 Sep;8(12):5574–5576.
   PubMed Web of Science ®Google Scholar
• Passlick B, Izbicki JR, Kubuschok B, et al. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol. 1994 Sep;12(9):1827–1832.
   PubMed Web of Science ®Google Scholar
• Schlimok G, Funke I, Holzmann B, et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8672–8676.
   PubMed Web of Science ®Google Scholar
• Magbanua MJ, Das R, Polavarapu P, et al. Approaches to isolation and molecular characterization of disseminated tumor cells. Oncotarget. 2015 Oct 13;6(31):30715–30729.
   PubMedGoogle Scholar
• Fehm T, Braun S, Muller V, et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer. 2006 Sep 1;107(5):885–892.
   PubMed Web of Science ®Google Scholar
• Polzer B, Medoro G, Pasch S, et al. Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med. 2014 Nov;6(11):1371–1386.
   PubMed Web of Science ®Google Scholar
• Lin E, Cao T, Nagrath S, et al. Circulating tumor cells: diagnostic and therapeutic applications. Annu Rev Biomed Eng. 2018 Jun;4(20):329–352.
   Google Scholar
• Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res off J Am Assoc Cancer Res. 2004 Oct 15;10(20):6897–6904.
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008 Jul 1;26(19):3213–3221.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug 19;351(8):781–791.
   PubMed Web of Science ®Google Scholar
• Hiraiwa K, Takeuchi H, Hasegawa H, et al. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol. 2008 Nov;15(11):3092–3100.
   PubMed Web of Science ®Google Scholar
• Thalgott M, Rack B, Maurer T, et al. Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol. 2013 May;139(5):755–763.
   PubMed Web of Science ®Google Scholar
• Rack B, Schindlbeck C, Juckstock J, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014 May 15;106(5):dju066.
   PubMedGoogle Scholar
• Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014 Apr;15(4):406–414.
   PubMed Web of Science ®Google Scholar
• Janni WJ, Rack B, Terstappen LW, et al. Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2016 May 15;22(10):2583–2593.
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012 Jun 14;10(6):717–728.
   PubMed Web of Science ®Google Scholar
• Holcomb IN, Grove DI, Kinnunen M, et al. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res. 2008 Jul 15;68(14):5599–5608.
   PubMed Web of Science ®Google Scholar
• Hosseini H, Obradovic MMS, Hoffmann M, et al. Early dissemination seeds metastasis in breast cancer. Nature. 2016 Dec 22;540(7634):552–558.
   PubMed Web of Science ®Google Scholar
• Stoecklein NH, Hosch SB, Bezler M, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell. 2008 May;13(5):441–453.
   PubMed Web of Science ®Google Scholar
• Weckermann D, Polzer B, Ragg T, et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009 Apr 1;27(10):1549–1556.
   PubMed Web of Science ®Google Scholar
• Werner-Klein M, Scheitler S, Hoffmann M, et al. Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma. Nat Commun. 2018 Feb 9;9(1):595.
   PubMedGoogle Scholar
• Hoffmann M, Pasch S, Schamberger T, et al. Diagnostic pathology of early systemic cancer: ERBB2 gene amplification in single disseminated cancer cells determines patient survival in operable esophageal cancer. Int J Cancer. 2018 Feb 15;142(4):833–843.
   PubMed Web of Science ®Google Scholar
• Ditsch N, Mayer B, Rolle M, et al. Estrogen receptor expression profile of disseminated epithelial tumor cells in bone marrow of breast cancer patients. Recent Results Cancer Res Fortschritte der Krebsforschung Progres Dans les Recherches Sur le Cancer. 2003;162:141–147.
   PubMedGoogle Scholar
• Fehm T, Krawczyk N, Solomayer EF, et al. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. BCR. 2008;10(5):R76.
   PubMed Web of Science ®Google Scholar
• Magbanua MJM, Rugo HS, Hauranieh L, et al. Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. NPJ Breast Cancer. 2018;4:31.
   PubMed Web of Science ®Google Scholar
• Krawczyk N, Banys M, Neubauer H, et al. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 2009 Oct;29(10):4019–4024.
   PubMed Web of Science ®Google Scholar
• Rack B, Zombirt E, Trapp E, et al. Comparison of HER2 expression in primary tumor and disseminated tumor cells in the bone marrow of breast cancer patients. Oncology. 2016;90(4):232–238.
   PubMed Web of Science ®Google Scholar
• Wulfing P, Borchard J, Buerger H, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res off J Am Assoc Cancer Res. 2006 Mar 15;12(6):1715–1720.
   PubMed Web of Science ®Google Scholar
• Ellsworth DL, Blackburn HL, Shriver CD, et al. Single-cell sequencing and tumorigenesis: improved understanding of tumor evolution and metastasis. Clini Transl Med. 2017 Dec;6(1):15.
   PubMed Web of Science ®Google Scholar
• Lee JK, Liu Z, Sa JK, et al. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nature Genet. 2018 Oct;50(10):1399–1411.
   PubMed Web of Science ®Google Scholar
• Rodon J, Soria JC, Berger R, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 May;25(5):751–758.
   PubMed Web of Science ®Google Scholar
• Yu KH, Snyder M. Omics profiling in precision oncology. Mol Cell Proteomics. 2016 Aug;15(8):2525–2536.
   PubMed Web of Science ®Google Scholar
• Chappell L, Russell AJC, Voet T. Single-cell (multi)omics technologies. Annu Rev Genomics Hum Genet. 2018 Aug;31(19):15–41.
   Google Scholar
• Gruber I, Fehm T, Taran FA, et al. Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer. Breast Cancer Res Treat. 2014 Apr;144(2):353–360.
   PubMed Web of Science ®Google Scholar
• Xenidis N, Ignatiadis M, Apostolaki S, et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol. 2009 May 1;27(13):2177–2184.
   PubMed Web of Science ®Google Scholar
• Goodman CR, Seagle BL, Friedl TWP, et al. Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer. JAMA Oncol. 2018 Aug 1;4(8):e180163.
   PubMed Web of Science ®Google Scholar
• Bidard FC, Kirova YM, Vincent-Salomon A, et al. Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer. Ann Oncol. 2009 Nov;20(11):1836–1841.
   PubMed Web of Science ®Google Scholar
• Mignot F, Loirat D, Dureau S, et al. Disseminated tumor cells predict efficacy of regional nodal irradiation in early stage breast cancer. Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):389–396.
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Bozionelou V, Agelaki S, et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol. 2012 Jul;23(7):1744–1750.
   PubMed Web of Science ®Google Scholar
• Naume B, Synnestvedt M, Falk RS, et al. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer. J Clin Oncol. 2014 Dec 1;32(34):3848–3857.
   PubMed Web of Science ®Google Scholar
• Harper KL, Sosa MS, Entenberg D, et al. Mechanism of early dissemination and metastasis in Her2+ mammary cancer. Nature. 2016 Dec 22;540(7634):588–592.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Mose ES, Montel V, et al. Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. Am J Pathol. 2006 Aug;169(2):673–681.
   PubMed Web of Science ®Google Scholar
• Gangnus R, Langer S, Breit E, et al. Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res off J Am Assoc Cancer Res. 2004 May 15;10(10):3457–3464.
   PubMed Web of Science ®Google Scholar
• Solakoglu O, Maierhofer C, Lahr G, et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2246–2251.
   PubMed Web of Science ®Google Scholar
• Putz E, Witter K, Offner S, et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res. 1999 Jan 1;59(1):241–248.
   PubMed Web of Science ®Google Scholar
• Banko P, Lee SY, Nagygyorgy V, et al. Technologies for circulating tumor cell separation from whole blood. J Hematol Oncol. 2019 May 14;12(1):48.
   PubMedGoogle Scholar
• Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013 Jun;31(6):539–544.
   PubMed Web of Science ®Google Scholar
• Cayrefourcq L, Mazard T, Joosse S, et al. Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res. 2015 Mar 1;75(5):892–901.
   PubMed Web of Science ®Google Scholar
• Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014 Sep 25;159(1):176–187.
   PubMed Web of Science ®Google Scholar
• Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nature Med. 2014 Aug;20(8):897–903.
   PubMed Web of Science ®Google Scholar
• Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014 Jul 11;345(6193):216–220..
   PubMed Web of Science ®Google Scholar
• Brungs D, Minaei E, Piper AK, et al. Establishment of novel long-term cultures from EpCAM positive and negative circulating tumour cells from patients with metastatic gastroesophageal cancer. Sci Rep. 2020 Jan 17;10(1):539.
   PubMed Web of Science ®Google Scholar
• Girotti MR, Gremel G, Lee R, et al. Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma. Cancer Discov. 2016 Mar;6(3):286–299.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ridgway LD, Wetzel MD, et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med. 2013 Apr 10;5(180):180ra48.
   PubMed Web of Science ®Google Scholar
• Morrow CJ, Trapani F, Metcalf RL, et al. Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study. Ann Oncol. 2016 Jun;27(6):1155–1160.
   PubMed Web of Science ®Google Scholar
• Grillet F, Bayet E, Villeronce O, et al. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture. Gut. 2017 Oct;66(10):1802–1810.
   PubMed Web of Science ®Google Scholar
• Pereira-Veiga T, Abreu M, Robledo D, et al. CTCs-derived xenograft development in a triple negative breast cancer case. Int J Cancer. 2019 May 1;144(9):2254–2265.
   PubMed Web of Science ®Google Scholar
• Drapkin BJ, George J, Christensen CL, et al. Genomic and functional fidelity of small cell lung cancer patient-derived xenografts. Cancer Discov. 2018 May;8(5):600–615.
   PubMed Web of Science ®Google Scholar
• Vishnoi M, Liu NH, Yin W, et al. The identification of a TNBC liver metastasis gene signature by sequential CTC-xenograft modeling. Mol Oncol. 2019 Sep;13(9):1913–1926.
   PubMed Web of Science ®Google Scholar
• Faugeroux V, Pailler E, Oulhen M, et al. Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model. Nat Commun. 2020 Apr 20;11(1):1884.
   PubMed Web of Science ®Google Scholar
• Koch C, Kuske A, Joosse SA, et al. Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Mol Med. 2020 Sep 7;12(9):e11908.
   PubMed Web of Science ®Google Scholar
• Rivera-Baez L, Lohse I, Lin E, et al. Expansion of circulating tumor cells from patients with locally advanced pancreatic cancer enable patient derived xenografts and functional studies for personalized medicine. Cancers (Basel). 2020 Apr 20;12:4.
   Web of Science ®Google Scholar
• Khoo BL, Grenci G, Lim JSY, et al. Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention. Br J Cancer. 2019 Feb;120(4):407–423.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Shiratsuchi H, Lin J, et al. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget. 2014 Dec 15;5(23):12383–12397.
   PubMed Web of Science ®Google Scholar
• Stoecklein NH, Fischer JC, Niederacher D, et al. Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution. Expert Rev Mol Diagn. 2016;16(2):147–164.
   PubMed Web of Science ®Google Scholar
• Fischer JC, Niederacher D, Topp SA, et al. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16580–16585.
   PubMed Web of Science ®Google Scholar
• Gorges TM, Penkalla N, Schalk T, et al. Enumeration and molecular characterization of tumor cells in lung cancer patients using a novel in vivo device for capturing circulating tumor cells. Clin Cancer Res off J Am Assoc Cancer Res. 2016 May 1;22(9):2197–2206.
   PubMed Web of Science ®Google Scholar
• Peinado H, Zhang H, Matei IR, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017 May;17(5):302–317.
   PubMed Web of Science ®Google Scholar
• Narkhede AA, Crenshaw JH, Crossman DK, et al. An in vitro hyaluronic acid hydrogel based platform to model dormancy in brain metastatic breast cancer cells. Acta Biomater. 2020 Apr 15;107:65–77.
   PubMed Web of Science ®Google Scholar
• Pradhan S, Slater JH. Tunable hydrogels for controlling phenotypic cancer cell states to model breast cancer dormancy and reactivation. Biomaterials. 2019 Sep;215:119177.
   PubMed Web of Science ®Google Scholar
• Carpenter RA, Kwak JG, Peyton SR, et al. Implantable pre-metastatic niches for the study of the microenvironmental regulation of disseminated human tumour cells. Nature Biomed Eng. 2018 Dec;2(12):915–929.
   PubMed Web of Science ®Google Scholar
• Birey F, Andersen J, Makinson CD, et al. Assembly of functionally integrated human forebrain spheroids. Nature. 2017 May 4;545(7652):54–59.
   PubMed Web of Science ®Google Scholar
• Mazzocchi AR, Rajan SAP, Votanopoulos KI, et al. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening. Sci Rep. 2018 Feb 13;8(1):2886.
   PubMedGoogle Scholar
• Misra S, Moro CF, Del Chiaro M, et al. Ex vivo organotypic culture system of precision-cut slices of human pancreatic ductal adenocarcinoma. Sci Rep. 2019 Feb 14;9(1):2133.
   PubMedGoogle Scholar
• Neal JT, Li X, Zhu J, et al. Organoid modeling of the tumor immune microenvironment. Cell. 2018 Dec 13;175(7):1972–1988 e16.
   PubMed Web of Science ®Google Scholar
• Plummer S, Wallace S, Ball G, et al. A human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. Sci Rep. 2019 Feb 5;9(1):1407.
   PubMedGoogle Scholar
• Skardal A, Devarasetty M, Forsythe S, et al. A reductionist metastasis-on-a-chip platform for in vitro tumor progression modeling and drug screening. Biotechnol Bioeng. 2016 Sep;113(9):2020–2032.
   PubMed Web of Science ®Google Scholar
• Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun. 2018 May 15;9(1):1911.
   PubMedGoogle Scholar
• Matano M, Date S, Shimokawa M, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med. 2015 Mar;21(3):256–262.
   PubMed Web of Science ®Google Scholar
• Gao H, Korn JM, Ferretti S, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nature Med. 2015 Nov;21(11):1318–1325.
   PubMed Web of Science ®Google Scholar
• Izumchenko E, Paz K, Ciznadija D, et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol. 2017 Oct 1;28(10):2595–2605.
   PubMed Web of Science ®Google Scholar
• Pauli C, Hopkins BD, Prandi D, et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 2017 May;7(5):462–477.
   PubMed Web of Science ®Google Scholar
• Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018 Feb 23;359(6378):920–926.
   PubMed Web of Science ®Google Scholar